Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Effects of Combined Heat Application and Acupressure to the Carotid Artery Region on Cerebral Blood Flow in Healthy Adults

NCT07324226 · tracked via the Priya Life Science South Korea tracker
Phase
Not applicable
Started
2026-02-01
Last updated
2026-01-07

Condition(s) studied

Healthy Subjects/Volunteers

Investigational drug(s) / intervention(s)

Combined heat and acupressure

Combined heat and acupressure: Press the start button to activate the automatic mode. When the start button is pressed, the device operates for approximately 40 minutes. When the start button is pressed, acupressure massage is performed with a single back-and-forth cycle from acupressure bar No. 1 to No. 18. The device then performs back-and-forth acupressure massage between acupressure bars No. 18 and No. 13 for the remaining time. After operating for 40 minutes in automatic mode, the mattress heating unit, the acupressure bar heating unit, and the acupressure bar movement are all turned off. 1. Press the shoulder button. The acupressure bar operates in the neck-to-shoulder section (acupressure bars No. 1 to 6), and both the mattress heating unit and the acupressure bar heating unit are activated. 2. After operating for 20 minutes in manual mode, the mattress heating unit, the acupressure bar heating unit, and the acupressure bar movement are turned off.

Study summary

The aim of this study is to investigate the effects of combined heat application and acupressure to the carotid artery region on cerebral blood flow in healthy adults

Eligibility

Sex
ALL
Min age
40 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Adults aged 40 to 65 years. * Individuals with no history of cerebrovascular, cardiovascular, or neurological diseases. * Individuals who have signed the informed consent form and voluntarily agreed to participate in the study Exclusion Criteria: * Individuals with a history of cerebrovascular, cardiovascular, or neurological diseases (e.g., stroke, angina, epilepsy). Individuals currently taking medications that may affect cerebral blood flow (such as antihypertensive agents or antidepressants). Individuals with skin diseases or lesions that make it difficult to apply heat or acupressure devices to the carotid artery region, and individuals who are pregnant or breastfeeding. Individuals with a history of seizures. Individuals who have participated in clinical studies two or more times in the same year, or who have participated in another clinical study within the past 6 months. Individuals who, in the judgment of the principal investigator or sub-investigator, have clinically significant findings that make them unsuitable for participation in this study.

Primary outcome measure(s)

  • A SPECT CT brain scan — In the post-SPECT protocol, the radiopharmaceutical will be administered at 5 minutes (n=3), 10 minutes (n=3), and 20 minutes (n=3) after the start of image acquisition.
    Cerebral blood flow change rate analysis: For each participant, the percentage change in cerebral blood flow (CBF) observed on SPECT imaging compared with the baseline time point will be quantitatively analyzed at the following three time points. Radiopharmaceutical injection reference times: 5 minutes, 10 minutes, and 20 minutes after injection.

Trial sites (1)

FacilityCityRegionStatus
Rehab lab, Pusan National University Yangsan Hospital Yangsan Gyeongsangnam-do Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07324226 on ClinicalTrials.gov ↗ ← All trials in South Korea